Organovo Holdings Company Profile (NASDAQ:ONVO)

About Organovo Holdings (NASDAQ:ONVO)

Organovo Holdings logoOrganovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONVO
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $2.81
  • 200 Day Moving Avg: $3.18
  • 52 Week Range: $2.48 - $4.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.35
  • P/E Growth: 0.00
  • Average Volume: 922,323 shs.

Frequently Asked Questions for Organovo Holdings (NASDAQ:ONVO)

What is Organovo Holdings' stock symbol?

Organovo Holdings trades on the NASDAQ under the ticker symbol "ONVO."

How were Organovo Holdings' earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) issued its earnings results on Thursday, November, 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm earned $1.38 million during the quarter, compared to analysts' expectations of $0.50 million. View Organovo Holdings' Earnings History.

When will Organovo Holdings make its next earnings announcement?

Organovo Holdings is scheduled to release their next quarterly earnings announcement on Wednesday, June, 7th 2017. View Earnings Estimates for Organovo Holdings.

Where is Organovo Holdings' stock going? Where will Organovo Holdings' stock price be in 2017?

4 equities research analysts have issued twelve-month price targets for Organovo Holdings' stock. Their predictions range from $4.50 to $15.00. On average, they expect Organovo Holdings' stock price to reach $7.25 in the next twelve months. View Analyst Ratings for Organovo Holdings.

Who are some of Organovo Holdings' key competitors?

Who are Organovo Holdings' key executives?

Organovo Holdings' management team includes the folowing people:

  • Keith E. Murphy, Chairman of the Board
  • Taylor J. Crouch, President, Chief Executive Officer
  • Eric Michael David M.D. J.D., Executive Vice President - Pre-Clinical Development, Chief Strategy Officer
  • Sharon Collins Presnell Ph.D., Chief Scientific Officer
  • Jennifer Kinsbruner Bush J.D., Compliance Officer, General Counsel, Corporate Secretary
  • Paul Gallant, General Manager
  • Robert F. Baltera Jr., Lead Independent Director
  • James T. Glover, Independent Director
  • Richard A. Heyman Ph.D., Independent Director
  • Tamar D. Howson, Independent Director

Who owns Organovo Holdings stock?

Organovo Holdings' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), UBS Group AG (0.00%), Geode Capital Management LLC (0.00%), Morgan Stanley (0.00%), Bank of New York Mellon Corp (0.00%) and Schwab Charles Investment Management Inc. (0.00%). Company insiders that own Organovo Holdings stock include Eric David and Keith Murphy. View Institutional Ownership Trends for Organovo Holdings.

Who sold Organovo Holdings stock? Who is selling Organovo Holdings stock?

Organovo Holdings' stock was sold by a variety of institutional investors in the last quarter, including Quantitative Investment Management LLC, Morgan Stanley, Credit Suisse AG, Wells Fargo & Company MN, ProShare Advisors LLC, Granite Investment Partners LLC, Messner & Smith Theme Value Investment Management Ltd. CA and TIAA CREF Investment Management LLC. Company insiders that have sold Organovo Holdings stock in the last year include Eric David and Keith Murphy. View Insider Buying and Selling for Organovo Holdings.

Who bought Organovo Holdings stock? Who is buying Organovo Holdings stock?

Organovo Holdings' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Meridian Wealth Management LLC, UBS Group AG, Geode Capital Management LLC, Schwab Charles Investment Management Inc., KCG Holdings Inc., Essex Investment Management Co. LLC and Tudor Investment Corp ET AL. View Insider Buying and Selling for Organovo Holdings.

How do I buy Organovo Holdings stock?

Shares of Organovo Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Organovo Holdings' stock price today?

One share of Organovo Holdings stock can currently be purchased for approximately $2.94.

MarketBeat Community Rating for Organovo Holdings (NASDAQ ONVO)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about Organovo Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Organovo Holdings (NASDAQ:ONVO) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.25 (146.60% upside)

Analysts' Ratings History for Organovo Holdings (NASDAQ:ONVO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/16/2017Jefferies Group LLCReiterated RatingBuy$4.50HighView Rating Details
1/25/2017Raymond James Financial, Inc.Initiated CoverageOutperform$5.00N/AView Rating Details
12/15/2016BTIG ResearchInitiated CoverageBuy$15.00N/AView Rating Details
11/28/2016Evercore ISIInitiated CoverageBuy$4.50N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Organovo Holdings (NASDAQ:ONVO)
Earnings by Quarter for Organovo Holdings (NASDAQ:ONVO)
Earnings History by Quarter for Organovo Holdings (NASDAQ ONVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2017Q3 2017($0.10)($0.09)$1.40 million$1.15 millionViewListenView Earnings Details
11/3/2016Q217($0.11)($0.10)$0.50 million$1.38 millionViewListenView Earnings Details
8/4/2016Q1($0.10)($0.09)$0.30 million$0.89 millionViewListenView Earnings Details
6/9/2016Q4($0.11)($0.09)$0.10 million$0.55 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Organovo Holdings (NASDAQ:ONVO)
Current Year EPS Consensus Estimate: $-0.40 EPS
Next Year EPS Consensus Estimate: $-0.40 EPS


Dividend History for Organovo Holdings (NASDAQ:ONVO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Organovo Holdings (NASDAQ:ONVO)
Insider Trades by Quarter for Organovo Holdings (NASDAQ:ONVO)
Institutional Ownership by Quarter for Organovo Holdings (NASDAQ:ONVO)
Insider Trades by Quarter for Organovo Holdings (NASDAQ:ONVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/9/2017Keith MurphyCEOSell25,000$3.68$92,000.00View SEC Filing  
1/24/2017Keith MurphyCEOSell25,000$3.51$87,750.00View SEC Filing  
12/14/2016Keith MurphyCEOSell50,000$3.72$186,000.00View SEC Filing  
8/5/2016Eric DavidEVPSell20,000$4.55$91,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Organovo Holdings (NASDAQ:ONVO)
Latest Headlines for Organovo Holdings (NASDAQ:ONVO)
DateHeadline logoOrganovo Holdings, Inc. breached its 50 day moving average in a Bullish Manner : ONVO-US : May 29, 2017 - May 29 at 8:34 AM logoOrganovo Holdings Inc (ONVO) Expected to Announce Earnings of -$0.11 Per Share - May 29 at 8:22 AM logoAnalysts Anticipate Organovo Holdings Inc (ONVO) to Post ($0.11) Earnings Per Share - May 26 at 2:30 PM logoOrganovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced Therapies and Regenerative Medicine Congress - May 19 at 11:49 AM logoOrganovo Announces Release Date for Fiscal Fourth-Quarter 2017 Financial Results - May 17 at 8:45 AM logoOrganovo Holdings, Inc. breached its 50 day moving average in a Bullish Manner : ONVO-US : May 17, 2017 - May 17 at 8:45 AM logoHere's Why Organovo Holdings Stock Fell 5.2% In April - May 11 at 9:03 AM logoResearch Reports Initiation on Medical Labs Stocks -- Organovo, DexCom, Quest ... - May 9 at 11:17 AM logo$630,000.00 in Sales Expected for Organovo Holdings Inc (ONVO) This Quarter - May 5 at 1:38 PM logo Organovo Holdings Inc (ONVO) Given Consensus Rating of "Strong Buy" by Brokerages - May 4 at 9:16 AM logoOrganovo Holdings (ONVO) Receives Daily Media Impact Rating of 0.15 - May 4 at 12:40 AM logo-$0.11 EPS Expected for Organovo Holdings Inc (ONVO) This Quarter - May 3 at 8:24 PM logoOrganovo Holdings, Inc. – Value Analysis (NASDAQ:ONVO) : May 3, 2017 - May 3 at 8:00 PM logoSomewhat Positive Press Coverage Unlikely to Impact Organovo Holdings (ONVO) Share Price - April 30 at 3:26 PM logoFavorable Press Coverage Likely to Impact Organovo Holdings (ONVO) Stock Price - April 28 at 12:36 AM logoClearside Biomedical, Inc. Announces Completion Of Patient Enrollment In Phase 1/2 Open Label Clinical Trial Of CLS-TA In Diabetic Macular Edema - April 20 at 9:07 AM logoOrganovo Holdings (ONVO) Given Daily News Impact Score of -0.29 - April 19 at 11:54 AM logoOrganovo Holdings Inc (ONVO) Stock Rating Upgraded by Zacks Investment Research - April 18 at 7:54 AM logoBrokerages Expect Organovo Holdings Inc (ONVO) to Post ($0.11) EPS - April 17 at 6:37 PM logoOrganovo Holdings (ONVO) Given Daily Media Sentiment Score of 0.44 - April 15 at 10:07 AM logoOrganovo Holdings Inc (ONVO) Upgraded by Zacks Investment Research to Hold - April 14 at 10:06 AM logoOrganovo Holdings CEO Leaves: Should Investors Be Worried? - Motley Fool - April 14 at 8:03 AM logoWhat's Next for Organovo Holdings Inc.? - Motley Fool - April 12 at 7:59 PM logoOrganovo Holdings Inc (ONVO) Short Interest Down 4.3% in March - April 12 at 4:22 PM logo Analysts Expect Organovo Holdings Inc (ONVO) to Announce -$0.10 EPS - April 12 at 4:09 PM logo2 inmates charged with killing 4 in South Carolina prison - USA TODAY - April 8 at 6:17 PM logoTrump Shifts Course on Egypt, Praising Its Authoritarian Leader - New York Times - April 3 at 6:24 PM logoChina Learns How to Get Trump's Ear: Through Jared Kushner - New York Times - April 2 at 10:53 AM logoSenate panel to vote on Supreme Court nominee Neil Gorsuch - USA TODAY - April 2 at 10:53 AM logoMichael Flynn left Russian speaking fees off initial financial disclosures - CNN - April 2 at 10:53 AM logoPart of I-85 collapses in Atlanta after massive fire - March 31 at 12:21 AM logoWhite House adviser Jared Kushner to appear before Senate Intelligence Committee - March 27 at 9:55 AM logoKhalid Masood: From popular teen to murderous extremist - CNN - March 25 at 6:39 PM logoUS-Led Coalition Confirms Strikes Hit Mosul Site Where Civilians Died - New York Times - March 25 at 6:39 PM logoLas Vegas Strip shooting leaves one dead and one wounded - CNN - March 25 at 6:39 PM logo Organovo Holdings Inc (ONVO) Given $4.50 Consensus Target Price by Brokerages - March 24 at 12:22 PM logoMedical Laboratories Stocks Under Scanner -- Organovo, DexCom, Quest Diagnostics, and Alere - March 22 at 9:08 AM logoJefferies Group LLC Reiterates "Buy" Rating for Organovo Holdings Inc (ONVO) - March 22 at 8:20 AM logoOrganovo Collaborates With Professor Melissa Little for Kidney Tissue Research - GlobeNewswire (press release) - January 24 at 8:58 AM logoBetter Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc. - January 5 at 11:54 AM logoOrganovo to Present on December 14 in a Live Interactive Webcast at - December 7 at 6:57 PM logoOrganovo (ONVO) presents at Canaccord Genuity Medical Technology & Diagnostics Forum - Slideshow - November 18 at 6:14 PM logoTechnical Reports on Healthcare Equities -- Organovo, Quest Diagnostics, Alere, and DexCom - November 16 at 10:21 AM logoHow Much Is Organovo Holdings, Inc. Really Worth? - November 10 at 9:44 AM logoEdited Transcript of ONVO earnings conference call or presentation 3-Nov-16 9:00pm GMT - November 4 at 6:09 PM



Organovo Holdings (ONVO) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff